DEA Places Insomnia Drug Into Schedule IV

The Drug Enforcement Administration is placing the newly approved drug Quiviviq (daridorexant) in Schedule IV of the Controlled Substances Act, it said in an interim final rule. Effective April 7, daridorexant, which was granted FDA approval in January, is subject to new registration, labeling, record-keeping, and import and export requirements. DEA is accepting comments on the rule until May 9.